Back to Quality Research
INVAInnoviva Inc
Health Care · Biotechnology: Pharmaceutical Preparations · Small
$20.66−1.90%
As of 23 Oct 2026Mkt cap $1.5B
Stage 13
WATCH
Fundamentals
57.3/75
Technical
8.2/15
Independent
65.5/90
GCAE viewbusiness is credible but technical recovery is not yet actionable
Price
- 1M
- 0.0%
- 3M
- −3.0%
- 6M
- −12.3%
- 1Y
- +12.6%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 5.0xHist median 13.7x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 9.2x
- FCF yield
- 10.8%
Quality
- ROIC
- 15.8%
- Operating margin
- 39.8%
- FCF margin
- 47.6%
- Current ratio
- 14.6x
Growth
- Revenue growth
- +14.7%Latest FY YoY
- Revenue CAGR
- +1.2%
- EPS CAGR
- +3.6%
- FCF CAGR
- −14.3%
Capital
- Share-count trend
- −1.2%3Y annualised
- Net cash
- $290M-1.5x OCF
Annual trend
- CAGR 2021–2025
- +1.2%
- Latest · 2025
- $0B
- YoY
- +14.7%
GCAE Research
- Quality Research
- PRE-AI
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- WATCH · CURRENT
Key takeaway
Attractive economics and valuation; investment fair-value complexity keeps it on watch.
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-04
More details & evidence
Production decision
- Stage 13
- WATCH
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded